Our mission is to be the leading provider of equity research in healthcare and life sciences

We produce institutional­ quality equity research on small/mid­cap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.



Research Clients



Reports published



Readers in database

Receipt of UK approvals means @scancellpharma can initiate its SCIB1 #ImmunoBody Phase II study in #metastatic #melanoma patients receiving #Keytruda during Q219. Opening of the US arm is pending @US_FDA IND approval.
Read our note: https://t.co/TQFlgNDMKu

.@MaxCyte_info reports today that its sales rose by 19% in FY18, with a 24% CAGR over the past four years, and we believe double-digit revenue growth should be sustained for the foreseeable future. Read our $MXCT note at: https://t.co/I9vIBMeb3C

Merger between @MereoBioPharma and @OncoMed_Pharma has been completed, Mereo to start trading on @Nasdaq tomorrow

Data so far suggests that bemcentinib can enhance activity of pembrolizumab in NSCLC, in particular in PD-L1 negative patients. Also, impressive efficacy has already been seen in Axl-positive AML patients with bemcentinib monotherapy

.@BerGenBio will be presenting OS data from stage 1 of the Phase II NSCLC study with bemcentinib in combination with pembrolizumab, and initial efficacy data from stage 2 and data from the Phase II trial in AML with bemcentinib in combination with chemoat #ASCO19

Another paper which relies upon ANGLE plc's @Parsortix has been published. This time work by @MDAndersonNews on breast cancer has been published in the Nature publication @SciReports

Subscribe to our research

Please sign up here to be added to our distribution database